Prospective study analyzed the association between efficacy and adverse events by Atezolizumab immunotherapy and diversity or species of fecal microbiota in advanced /reccurent non-small cell lung cancer patients

Prospective study analyzed the association between efficacy and adverse events by Atezolizumab immunotherapy and diversity or species of fecal microbiota in advanced /reccurent non-small cell lung cancer patients - Prospective study analyzed the association between efficacy and adverse events by Atezolizumab immunotherapy and diversity or species of fecal microbiota in advanced /reccurent non-small cell lung cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041822

Enrollment

Registered

2020-10-01

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced/reccurent non-small cell lung cancer patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) pathologically or cytologically confirmed non-small cell lung cancer (2) >= 2o years at the time of informed consent (3) Planned to treat with Atezolizumab combined chemotheapy or Atezolizumab monotherapy (4) Informed consent obtained from patients (5) Cases that feces can be collected

Exclusion criteria

Exclusion criteria: (1) Inadequate cases judged by doctors

Design outcomes

Primary

Measure	Time frame
Relapse-free 6 months survival according to the diversity and specific species of fecal microbiota. Overall 12 months survival according to the diversity and specific species of fecal microbiota. The incident rates of immune-related adverse events (>= Grade3) according to the diversity and specific species of fecal microbiota.	—

Countries

Japan

Contacts

Public ContactFumihiro Shoji

National Hospital Organization Kyushu Medical Center Department of Thoracic Surgery

fshoji@surg2.med.kyushu-u.ac.jp092-852-0700

Outcome results